The proprietary rPRO Technology ™ that drives LFB S.A.'s product development enables production of innovative recombinant therapies that are more cost-effective and scalable compared to traditionally …

Framingham biopharmaceutical firm LFB USA has pinned plans to build a new 65,000-square-foot manufacturing and laboratory facility in Marlborough in part on the expectation that its drug, ATryn, …

Within the LFB Group, which is a leader in the field of therapeutic proteins in France, LFB USA enables the production of life-saving medicines within the Group’s key areas of expertise and focus – …

For a link to the FDA article: https://www.fda.gov/news-events/press-announcements/fda-approves-additional-treatment-adults-and-adolescents-hemophilia-or-b-and-inhibitors Click here for the official …

LFB USA offers the comprehensive benefits you'd expect from a progressive biotechnology company — including health, dental, life insurance, flexible spending accounts, vacation time and 401 (k). Learn …

This Phase 3 trial study is being sponsored by LFB S.A.’s US subsidiary. “We are very pleased to have reached our patient enrollment target so quickly,” said Christian Béchon, Chairman and Chief …

FRAMINGHAM, MA, March 3, 2014 —LFB S.A., through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor …

Greater cost efficiency High protein purity These innovative recombinant therapies are more cost-effective and scalable to produce than their predecessors. Less cost and easier production means …

LFB is a biopharmaceutical group that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, including …

LFB is seeking to build on Crowley Drive, home to the Marlborough Gateway Business Park. LFB would join other companies that have recently expanded or moved operations west to Marlborough from …